Evidence map›Paper›PMID 25152895›Full record

ArticleJournal of immunology research2014

Dose of incorporated immunodominant antigen in recombinant BCG impacts modestly on Th1 immune response and protective efficiency against Mycobacterium tuberculosis in mice.

Hui Ma, Kang Wu, Fang Liu, Hua Yang, Han Kang, Ning-Ning Chen, Qin Yuan, Wen-Jiang Zhou, Xiao-Yong Fan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hui MaShanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.
Kang WuShanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.ORCID 0000-0002-9024-795X
Fang LiuShanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.
Hua YangShanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.
Han KangShanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China ; Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Ning-Ning ChenShanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.
Qin YuanShanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.
Wen-Jiang ZhouShanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.
Xiao-Yong FanShanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China ; Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, Shanghai 200032, China.ORCID 0000-0001-6654-3559
Shanghai Public Health Clinical Center · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One approach for improving BCG efficacy is to utilize BCG as vehicle to develop recombinant BCG (rBCG) strains overexpressing Mycobacterium tuberculosis (M. tb) antigens. Also expression level of a candidate antigen should impact the final T cell responses conferred by rBCG. In this study, based on our previously constructed differential expression system, we developed two rBCG strains overexpressing M. tb chimeric antigen Ag856A2 (coding a recombinant ag85a with 2 copies of esat-6 inserted at Acc I site of ag85a) at differential levels under the control of the subtly modified furA promoters. These two rBCG strains were used to vaccinate C57BL/6 mice and exploit dose of incorporated antigen in rBCG to optimize immune response and protective efficiency against M. tb challenge in mouse model. The results showed that rBCG strains overexpressing Ag856A2 at differential levels induced different antigen-specific IFN-γ production and comparable number of M. tb-specific CD4 T cells expressing IL-2. M. tb challenge experiment showed that rBCG strains afforded enhanced but comparable immune protection characterized by reduced bacillary load, lung pathology, and inflammation. These results suggested that the dose of antigens incorporated in rBCG can impact T cell immune responses but imposed no significantly differential protective efficacies.

Indexed as

AnimalsAntigens, BacterialBCG VaccineCD4-Positive T-LymphocytesDisease Models, AnimalEpitopes, T-LymphocyteFemaleImmunizationImmunodominant EpitopesInterferon-gammaInterleukin-2LungMiceMycobacterium bovisMycobacterium tuberculosisNitric Oxide Synthase Type IIAntigens, BacterialBCG VaccineEpitopes, T-LymphocyteImmunodominant EpitopesInterferon-gammaInterleukin-2Nitric Oxide Synthase Type IIRecombinant Fusion ProteinsTumor Necrosis Factor-alpha

Identifiers

PMID25152895
PMCPMC4134796
OpenAlexW2071165227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.